Marker Therapeutics Current Deferred Revenue (Quarterly) Analysis

Marker Therapeutics, Inc. (MRKR)

1.52 +0.08 (+5.92%) USD | NASDAQ | Dec 29, 16:00

1.53 +0.01 (+0.66%) Pre-Market: 09:04

View Current Deferred Revenue (Quarterly) for MRKR.
Upgrade now.

Sep '18

Jan '19

May '19

285.00

270.00

255.00

240.00

View Current Deferred Revenue (Quarterly) Chart

Start Trial

View Historical Data

Start Trial

View Current Deferred Revenue (Quarterly) Range, Past 5 Years

Start Trial

Minimum

Maximum

Average

Median

View Current Deferred Revenue (Quarterly) Benchmarks

Start Trial

ADMA Biologics, Inc.	Upgrade
Neurocrine Biosciences, Inc.	--
AIM ImmunoTech, Inc.	--
Protalix Biotherapeutics, Inc.	Upgrade
Armata Pharmaceuticals, Inc.	--